Human Medications, Human Drugs, Animal Medications, Animal Drugs, Pharmacy law, Pharmaceutical law, Compounding law, Sterile and Non Sterile Compounding 797 Compliance, Veterinary law, Veterinary Compounding Law; Health Care; Awareness of all Types of Compounding Issues; Pharmacy Benefit Managers (PBMs), Outsourcing Facilities Food and Drug Administration and Compliance Issues
Saturday, July 26, 2014
Second Question of the Day July 26, 2014 Is the compounding industry crashing like the stock market has in the past? Between the DQSA, less insurance companies and PBMs willing to reimbused, the on going civil and criminal litigation, all the issues the FDA is finding during the inspections, and the amount of recalls since NECC how much more can the industry survive before it decides to change the way it does business?
JAMA Extemporaneous Formulation or Compounding of Corticosteroids for Topical Usage
A number of extemporaneous corticosteroid preparations have been suggested in the literature. Unfortunately, this compounding of the corticosteroid and base is sometimes done without regard to the ultimate activity and stability of the product. A representative prescription filled by six pharmacies was compared with commercially formulated material. None of the six prescriptions was generally acceptable from the standpoint of pharmaceutical compounding, and all were inactive when tested in vasoconstriction studies.
more information found here
more information found here
DrugMonkey: Your Pharmacist May Hate You: Once Again, Real Life Takes Away My Material. I Al...
Your Pharmacist May Hate You: Once Again, Real Life Takes Away My Material. I Al...: Those of you who've picked up a copy of my awesome first book no doubt remember how I opened it with reminiscences of how I used to moc...
FDA takes on another compounder
FDA Takes on Another Compounder for GMP Violations
July 23, 2014
The FDA released its fourth warning letter in two days against a compounding pharmacy, this time chiding a large compounder for a mixture of quality violations at its four facilities. Read More
Must read! Study shows compounded oral liquids for perdiatric patients poses a significant risk to patient safety!
Variability in compounding of oral liquids for pediatric patients: A patient safety concern
Janis M. Rood; Melanie J. Engels; Scott L. Ciarkowski; Larry D. Wagenknecht; Chris J. Dickinson; James G. Stevenson
J Am Pharm Assoc (2003) 2014;54:383-389. doi:10.1331/JAPhA.2014.13074
Objective To determine the degree in variation of oral liquid pediatric compounding practices in Michigan pharmacies.
Design Cross-sectional survey study.
Setting All types of inpatient and outpatient pharmacies across the state of Michigan, excluding nuclear pharmacies and long-term care facilities.
Participants 244 Michigan pharmacies.
Intervention An online survey tool was used to assess the current compounding practices of 147 oral liquid pediatric medications. The survey was e-mailed or faxed to hospitals, chain pharmacies, and independent pharmacies. Pharmacists were also mailed a follow-up postcard, and the Michigan Pharmacists Association publicized the project through its journal and annual meeting.
Main outcome measures Pharmacy demographics; number of compounding pharmacies; number of medications compounded; awareness of compounding errors; results of compounding errors; and number of concentrations compounded per medication.
Results The majority of respondents were from outpatient pharmacies, but inpatient and other types of pharmacies were also represented. The majority of participating pharmacies compound fewer than five oral liquid medications per week. Awareness of errors was low overall, with no errors believed to result in permanent harm or death. The number of concentrations compounded per medication ranged from 1 to 9, with the majority of pharmacies compounding more than 3 concentrations per medication.
Conclusion There is a considerable degree of variation in current oral pediatric liquid compounding practices in Michigan pharmacies. This variability poses a significant risk to patient safety.
more information found here
5 reasons now may not be the time to be a compounding sales or marketing representative
1. Insurance companies have caught on to the inflated billing practices of compounding pharmacies and are scaling back on reimbursements
2. Once the compounding industry starts to lose profit some of the first people to be cut will be compounding sales and marketing representatives
3. Some compounding pharmacies are committing health care fraud or involved in activities that are against the law
4. Some compounding pharmacies sell products that kill or cause life-long illness just look at Apothecure, Franck's, Landmark, and NECC to name a few
5. If the deal and promises of income sound too good to be true, they probably are.
2. Once the compounding industry starts to lose profit some of the first people to be cut will be compounding sales and marketing representatives
3. Some compounding pharmacies are committing health care fraud or involved in activities that are against the law
4. Some compounding pharmacies sell products that kill or cause life-long illness just look at Apothecure, Franck's, Landmark, and NECC to name a few
5. If the deal and promises of income sound too good to be true, they probably are.
Subscribe to:
Posts (Atom)